Brokerages Set Genmab A/S Sponsored ADR (NASDAQ:GMAB) Price Target at $39.50

Genmab A/S Sponsored ADR (NASDAQ:GMAB) has earned a consensus recommendation of “Moderate Buy” from the thirteen brokerages that are presently covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $39.50.

A number of brokerages have commented on GMAB. HC Wainwright raised their price objective on Genmab A/S from $38.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday, July 2nd. BNP Paribas Exane upgraded Genmab A/S from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, April 22nd. Truist Financial began coverage on Genmab A/S in a research note on Wednesday, May 27th. They issued a “buy” rating and a $40.00 target price for the company. Guggenheim raised their target price on Genmab A/S from $40.00 to $42.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Finally, The Goldman Sachs Group upgraded shares of Genmab A/S from a “neutral” rating to a “buy” rating in a research note on Wednesday, April 22nd.

Hedge Funds Weigh In On Genmab A/S

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. CIBC Private Wealth Group LLC increased its stake in Genmab A/S by 291.9% in the fourth quarter. CIBC Private Wealth Group LLC now owns 827 shares of the company’s stock valued at $25,000 after acquiring an additional 616 shares during the period. Osaic Holdings Inc. lifted its stake in Genmab A/S by 37.8% during the second quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock worth $33,000 after purchasing an additional 440 shares during the period. V Square Quantitative Management LLC bought a new position in Genmab A/S during the first quarter worth about $34,000. NewEdge Advisors LLC boosted its holdings in Genmab A/S by 1,229.0% during the third quarter. NewEdge Advisors LLC now owns 1,236 shares of the company’s stock valued at $38,000 after purchasing an additional 1,143 shares in the last quarter. Finally, Brown Brothers Harriman & Co. boosted its holdings in Genmab A/S by 143.4% during the third quarter. Brown Brothers Harriman & Co. now owns 1,324 shares of the company’s stock valued at $41,000 after purchasing an additional 780 shares in the last quarter. 7.07% of the stock is owned by institutional investors.

Genmab A/S Price Performance

Shares of GMAB opened at $31.94 on Wednesday. The company has a 50-day simple moving average of $27.98 and a 200-day simple moving average of $27.93. The firm has a market capitalization of $19.92 billion, a P/E ratio of 25.15, a P/E/G ratio of 1.90 and a beta of 0.83. The company has a debt-to-equity ratio of 0.81, a quick ratio of 2.44 and a current ratio of 2.46. Genmab A/S has a 52 week low of $23.14 and a 52 week high of $35.43.

Genmab A/S (NASDAQ:GMAB) last released its earnings results on Thursday, August 6th. The company reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.37 by $0.17. Genmab A/S had a net margin of 19.08% and a return on equity of 14.89%. The business had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.12 billion. On average, equities research analysts expect that Genmab A/S will post 1.17 earnings per share for the current year.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.